"Vidarabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
Descriptor ID |
D014740
|
MeSH Number(s) |
D03.633.100.759.590.138.900 D13.570.065.950 D13.570.583.138.900
|
Concept/Terms |
Vidarabine- Vidarabine
- beta-Ara A
- beta Ara A
- Adenine Arabinoside
- Arabinoside, Adenine
- alpha-D-Arabinofuranosyladenine
- alpha D Arabinofuranosyladenine
- Ara A
- alpha-Ara A
- alpha Ara A
- Arabinofuranosyladenine
- Arabinosyladenine
- 9-beta-D-Arabinofuranosyladenine
- 9 beta D Arabinofuranosyladenine
- 9-beta-Arabinofuranosyladenine
- 9 beta Arabinofuranosyladenine
- Ara-A
|
Below are MeSH descriptors whose meaning is more general than "Vidarabine".
Below are MeSH descriptors whose meaning is more specific than "Vidarabine".
This graph shows the total number of publications written about "Vidarabine" by people in this website by year, and whether "Vidarabine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 1 | 0 | 1 |
2003 | 1 | 0 | 1 |
2006 | 1 | 0 | 1 |
2009 | 1 | 0 | 1 |
2012 | 0 | 1 | 1 |
2015 | 1 | 0 | 1 |
2017 | 3 | 5 | 8 |
2018 | 4 | 6 | 10 |
2019 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Vidarabine" by people in Profiles.
-
Fludarabine inhibits type I interferon-induced expression of the SARS-CoV-2 receptor angiotensin-converting enzyme 2. Cell Mol Immunol. 2021 07; 18(7):1829-1831.
-
Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report. J Med Case Rep. 2021 Feb 19; 15(1):90.
-
Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13). Int J Biol Macromol. 2020 Nov 15; 163:1687-1696.
-
Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (=60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT. Bone Marrow Transplant. 2020 04; 55(4):729-739.
-
First Report of a Patient With Natural Killer-Lymphoblastic Leukemia/Lymphoma in Korea. Ann Lab Med. 2019 Sep; 39(5):493-495.
-
Refining chemotherapy for chronic lymphocytic leukaemia with targeted drugs. Lancet Haematol. 2019 08; 6(8):e389-e390.
-
Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia. Blood Adv. 2018 11 27; 2(22):3102-3111.
-
Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation. Int J Hematol. 2019 Feb; 109(2):197-205.
-
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance. Leuk Lymphoma. 2019 03; 60(3):649-657.
-
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. Am J Hematol. 2018 10; 93(10):1211-1219.